Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX

A legfontosabb adatok

Ki végzi
Institute of Tropical Medicine, Belgium
Hol
Belgium, Burkina Faso és Mozambik3 helyszín, 3 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
458 fő vett részt
Kezdés
2023. dec. 13.
Befejezés
2025. dec. 9.
A vizsgálat típusa
Megfigyeléses, 7 csoport
A regiszteradat frissítve
2026. március 11.

Ki vehet részt

Életkor
1 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Age: ≥ 1 year
  • Willing and able to provide written informed consent (or assent for minors with written informed consent by parent(s) and/or guardian(s); Pilot:; -symptomatic for P. falciparum; -/Travel to P. falciparum endemic area within the last month; WP1:
  • Resident in Nanoro district
  • non-symptomatic individuals; WP2:
  • Positive for P. falciparum infection via Rapid Diagnostic Tests (RDT)
  • Age: ≥ 1 and ≤ 12 years
  • Patients are included when suspected of the following conditions:
  • Severe malaria by infection with P. falciparum is defined in the presence of P. falciparum asexual parasitemia, and as one or more of the following:
  • Impaired consciousness: A Blantyre coma score < 3 (when patients are ≤ 6 years) or Glasgow coma score < 10 (when patients are ≥ 6 years)
  • Prostration: Generalized weakness so that the person is unable to sit, stand or walk without assistance
  • Multiple convulsions: More than two episodes within 24 hours
  • Clinical manifestation of respiratory distress (e.g., rapid, deep and labored breathing)
  • Diagnosis through exclusion: absence of an identified alternative cause
  • Uncomplicated malaria by infection with P. falciparum is defined as a patient who presents with lethargic profile (e.g. fever) and a positive parasitological test for P. falciparum, but with no features of severe malaria

Ki nem vehet részt

  • Previous malaria treatment or prophylaxis in the last week
  • Delayed developmental status or history of chronic illness
  • Symptoms of malaria, as defined by presence of fever (body temperature >37.5 °C or history of fever during the past 48 hours) with a positive RDT (RDT are performed always when there is presence of fever)
  • A questionnaire will be used during the clinical assessment that addresses following exclusion criteria:; x Antimalarial drug treatment or other medication during the past week x If the patient had a meal within 4 hours before admission x Patients with acute meningitis (as clinically evaluated according to the local guidelines) x Patients with developmental delay or history of chronic illness x Vaccination during the past week
  • Participation in another study
  • Inability or unwillingness of the parents or guardians to provide informed consent; WP1:
  • Any plans to leave the study are in the coming 10 days; WP2:
  • Severe anemia (will be determined via clinical examination), since blood samples can hardly be withdrawn, co-morbidities

Hol van ez a vizsgálat?

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections.

A vizsgálat 7 csoportja

  • Pilot study Belgium Patients

    Patients (P. falciparum-infected) No intervention 6 ml of venous blood sampled at one time point

  • Pilot study Belgium Controls

    Control non-infected individuals No intervention 6 ml of venous blood sampled at one time point

  • Work package 1 Burkina Faso Asymptomatic

    Asymptomatic (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point. 300µl of finger prick blood at four follow-up visits 24, and 48 and 72h and day 10 after the enrollment.

  • Work package 1 Burkina Faso uncomplicated patients

    uncomplicated patients (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point.

  • Work package 1 Burkina Faso Uncomplicated Malaria Patients

    Control non-infected individuals No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

  • Work package 2 Mozambique Uncomplicated malaria patients

    Uncomplicated malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

  • Work package 2 Burkina Faso Severe malaria patients

    Severe malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. március 11.